Investor Information
Cleo Diagnostics is making accurate and early detection of ovarian cancer a reality
Cleo Diagnostics Limited (ASX:COV) is bringing to market a simple blood test for the accurate and early diagnosis of ovarian cancer, using its novel patented CXCL10 biomarker.
Cleo's first test - AdnexaSureTM is designed to distinguish benign from malignant growths and will be compatible with standard diagnostic laboratory workflows worldwide.
The platform is backed by over 10 years of scientific Research & Development at the Hudson Institute of Medical Research, with two clinical studies conducted in over 500 patients. Pursuant to a licence agreement with the Hudson Institute of Medical Research, Cleo has a worldwide exclusive licence to commercialise the intellectual property underpinning its operations and the ovarian cancer tests.
Cleo is advancing the availability of its simple blood test, under a modular execution strategy to ultimately address all ovarian cancer detection markets with specific tests including surgical triage, recurrence, high risk, and early-stage screening.
Why Invest in Cleo Diagnostics?
Strong intellectual property position with core foundational patent granted in Australia and USA (pending worldwide)
A simple blood test for accurate and early detection of Ovarian Cancer
Significant global total addressable cancer diagnostics market opportunity
Technology supported by gold-standard clinical evidence
Staged execution strategy focused on an achievable pathway to target markets
Experienced leadership team with credentials to execute
Cleo Diagnostics | Corporate Presentation | Feb 2024
Share Registry
XCEND Pty Ltd
C/- Level 2, 145 William Street
Darlinghurst NSW 2010
Phone (within Australia): (02) 7208 8033
Phone (outside Australia): +61 (2) 7208 8033
Website: www.xcend.co